News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Oscient Pharmaceuticals Corporation Provides Financial Projections For Fiscal Year 2006 And 2007
December 8, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today provided fiscal year 2006 and 2007 revenue guidance for its products, ANTARA® 130 mg (fenofibrate) capsules and FACTIVE® (gemifloxacin mesylate) tablets.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
·
6 min read
·
Lori Ellis
Layoff Tracker
Massachusetts-Based Karyopharm, Azurity Cut Workforces
July 14, 2025
·
158 min read
·
BioSpace Editorial Staff
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
·
1 min read
·
Dan Samorodnitsky
Infectious disease
Gilead to Provide New HIV Drug to Lower-Income Countries Through Novel Philanthropic Partnership
July 10, 2025
·
2 min read
·
Tristan Manalac
